Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 15/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 15/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 15/20 | 0.66 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166775 | 0.89 | HDAC1 (0.74) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4183793 | 0.86 | HDAC1 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4184856 | 0.86 | HDAC1 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4292077 | 0.82 | HDAC3 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4025219 | 0.82 | HDAC1 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6357495 | 0.81 | HDAC3 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4296790 | 0.81 | HDAC3 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4183242 | 0.80 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4019056 | 0.80 | HDAC3 (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4289921 | 0.80 | HDAC3 (0.74) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1755601-A2 | INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1664359-B1 | METHOD FOR SEPARATING TRIVALENT AMERICIUM FROM TRIVALENT CURIUM | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2007-01-03 | — | — | EP | claimed |
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | claimed |
| WO-2005086898-A2 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050197336-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-09-08 | — | — | US | claimed |
| US-20090203010-A1 | MSMB-gene based diagnosis, staging and prognosis of prostate cancer | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009089598-A2 | MSMB-GENE METHYLATION BASED DIAGNOSIS, STAGING AND PROGNOSIS OF PROSTATE CANCER | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2009-07-23 | — | — | WO | disclosed |
| EP-1755601-A2 | INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1664359-B1 | METHOD FOR SEPARATING TRIVALENT AMERICIUM FROM TRIVALENT CURIUM | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1664359-A1 | METHOD FOR SEPARATING TRIVALENT AMERICIUM FROM TRIVALENT CURIUM | FORSCHUNGSZENTRUM JÜLICH GMBH (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | disclosed |
| WO-2005086898-A2 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050197336-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-09-08 | — | — | US | disclosed |
| WO-2005021810-A1 | METHOD FOR SEPARATING TRIVALENT AMERICIUM FROM TRIVALENT CURIUM | Forschungszentrum Jülich GmbH (DE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197336-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HDAC3 6/4885HDAC4 11/4885HDAC1 1/4885 |
| US-20050250784-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | HDAC3 6/4885HDAC4 11/4885HDAC1 1/4885 |
| US-20090203010-A1 | MSMB-gene based diagnosis, staging and prognosis of prostate cancer | MAT2B, DNMT3B, SHBG | HDAC3 3834/4885HDAC4 2788/4885HDAC1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.